TY - JOUR
T1 - Encapsulation of stem-cell derived β-cells
T2 - A promising approach for the treatment for type 1 diabetes mellitus
AU - Neumann, Myriam
AU - Arnould, Thierry
AU - Su, Bao Lian
N1 - Funding Information:
The authors would like to thank Michel Savels from the University of Namur for his help with Fig. 3 . Myriam Neumann thanks the Fonds National de la Recherche Scientifique as she was a recipient of FRIA Doctoral Grant/Fellowship. The authors acknowledge the funding by the Federation Wallonia-Brussels Federation through the ARC (Action de Recherche Concertée) research programme (UNamur : 2022-2027; convention n°22/26-002).
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2023/4/15
Y1 - 2023/4/15
N2 - Type 1 diabetes mellitus is an auto-immune disease causing the T-cell mediated destruction of insulin-producing β-cells, resulting in chronic hyperglycemia. Current treatments such as insulin replacement therapy or the transplantation of pancreas or pancreatic islets present major disadvantages such as the constant need of drugs, as well as a shortage of donor organs. In this review, we discuss a sustainable solution to overcome these limitations combining the use of β-cells, derived from stem cells, and their encapsulation within a protective matrix. This article provides an exhaustive overview of currently investigated stem cell sources including embryonic, mesenchymal as well as induced pluripotent stem cells in combination with various up to date encapsulation methods allowing the formation of immuno-protective devices. In order to identify current limitations of this interdisciplinary therapeutic approach and to find sustainable solutions, it is essential to consider key aspects from all involved domains. This includes biological parameters such as the stem cell origin but also the different aspects of the encapsulation process, the used materials and their physico-chemical properties such as elasticity, porosity and permeability cut-off as well as the best implantation sites allowing efficient and self-autonomous control of glycemia by the transplanted encapsulated cells.
AB - Type 1 diabetes mellitus is an auto-immune disease causing the T-cell mediated destruction of insulin-producing β-cells, resulting in chronic hyperglycemia. Current treatments such as insulin replacement therapy or the transplantation of pancreas or pancreatic islets present major disadvantages such as the constant need of drugs, as well as a shortage of donor organs. In this review, we discuss a sustainable solution to overcome these limitations combining the use of β-cells, derived from stem cells, and their encapsulation within a protective matrix. This article provides an exhaustive overview of currently investigated stem cell sources including embryonic, mesenchymal as well as induced pluripotent stem cells in combination with various up to date encapsulation methods allowing the formation of immuno-protective devices. In order to identify current limitations of this interdisciplinary therapeutic approach and to find sustainable solutions, it is essential to consider key aspects from all involved domains. This includes biological parameters such as the stem cell origin but also the different aspects of the encapsulation process, the used materials and their physico-chemical properties such as elasticity, porosity and permeability cut-off as well as the best implantation sites allowing efficient and self-autonomous control of glycemia by the transplanted encapsulated cells.
KW - Diabetes
KW - Encapsulation
KW - Immune-isolation
KW - Pancreatic β-cells
KW - Stem cell differentiation
UR - http://www.scopus.com/inward/record.url?scp=85145965361&partnerID=8YFLogxK
U2 - 10.1016/j.jcis.2022.12.123
DO - 10.1016/j.jcis.2022.12.123
M3 - Article
C2 - 36623370
AN - SCOPUS:85145965361
SN - 0021-9797
VL - 636
SP - 90
EP - 102
JO - Journal of colloid and interface science
JF - Journal of colloid and interface science
ER -